Immunomodulatory peptide

Patent metadata

Field	Value
Publication number	US-11753452-B2
Application number	US-201816476788-A
Country	US
Kind code	B2
Filing date	Jan 12, 2018
Priority date	Jan 12, 2017
Publication date	Sep 12, 2023
Grant date	Sep 12, 2023

Abstract

Embodiments of the present disclosure relate to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO: 1, said peptide having a sequence of amino acids selected from the group consisting of: a) sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO: 1, and b) sequences of 3 to 39 amino acids having at least 70% identity with said sequence in a).

First claim

The invention claimed is:

1. A method of treating a subject with a condition responsive to activated cytotoxic functions of macrophages and characterized by expression of molecular patterns recognized by C-type lectin receptors, the method comprising administering to the subject a therapeutically effective amount of a medicament comprising a peptide, the peptide only consisting of a sequence of amino acids selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17,
wherein the peptide is amidated at the C-terminal and
wherein the peptide is a pro-inflammatory agent that increases expression of C-type lectin receptors on the surface of macrophages, thereby activating the cytotoxic functions of the macrophages when in contact with molecular patterns characterizing the condition.

2. The method according to claim 1 , wherein said peptide consists of the amino acid sequence SEQ ID NO: 1.

3. The method of claim 1 , wherein the condition is caused by a pathogen recognised by a C-type lectin receptor.

4. The method of claim 1 , wherein the condition is mycosis.

5. The method of claim 1 , wherein the condition is cancer with tumour cells having glycan patterns recognized by C-type lectin receptors.

6. The method of claim 3 , wherein the condition is caused by a pathogen recognised by a mannose or dectin-1 receptor.

7. The method of claim 4 , wherein the condition is candidiasis.

8. The method according to claim 1 , wherein the peptide has a sequence of amino acids selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

9. A method of activating a cytotoxic phenotype in macrophages, comprising contacting the macrophages with an effective amount of a medicament comprising a peptide, the peptide only consisting of a sequence of amino acids selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17,
wherein the peptide is amidated at the C-terminal, and
wherein the peptide is a pro-inflammatory agent that increases expression of C-type lectin receptors on the surface of the macrophages, whereby the cytotoxic functions of the macrophages are activated when in contact with molecular patterns recognized by C-type lectin receptors.

10. The method according to claim 9 , wherein said peptide consists of the amino acid sequence SEQ ID NO: 1.

11. The method according to claim 9 , wherein the method is a method for treating a disease in a subject caused by a pathogen recognised by a C-type lectin receptor, wherein contacting the macrophages with an effective amount of the medicament comprises administering to the subject a therapeutically effective amount of the medicament.

12. The method of claim 11 , wherein the pathogen is recognised by a mannose or dectin-1 receptor.

13. The method according to claim 11 , wherein the disease is mycosis.

14. The method of claim 11 , wherein the disease is candidiasis.

15. The method according to claim 9 , wherein the method is a method for treating of cancer in a subject characterized by tumour cells having glycan patterns recognized by C-type lectin receptors, wherein contacting the macrophages with an effective amount of the medicament comprises administering to the subject a therapeutically effective amount of the medicament.

16. The method according to claim 9 , wherein the peptide has a sequence of amino acids selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

Assignees

• Institut National Univ Jean Francois Champollion
• Univ Toulouse 3 Paul Sabatier
• Inst Nat Sante Rech Med
• Univ Rouen Normandie
• Institut Natl Univ Jean Francois Champollion

Inventors

• Benmoussa Khaddouj
• Bonnafe Elsa
• Coste Agnès
• Leprince Jérôme
• Pipy Bernard
• Treilhou Michel

Classifications

• C07K5/0808 Primary

  the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu · CPC title

• C07K14/43563 Primary

  from insects · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K5/101

  the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu · CPC title

• C07K7/08

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title